Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547806 · ClinicalTrials.gov registry record · Phase 2
Collection of Transplant Stem Cells for Plasma Cell Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01547806: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01547806 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547806, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
Background: \- One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant. Objectives: \- To collect stem cells for transplant as part of treatment for plasma cell myeloma. Eligibility: \- Individuals at least 18 years of age who will have chemotherapy and stem cell transplant for plasma cell myeloma. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have filgrastim injections for 5 days before collection. This will move stem cells from the bone marrow to the blood. * Participants will have apheresis to collect the stem cells. * Participants who need additional apheresis procedures to collect stem cells will have filgrastim and a dose of plerixafor to improve the collection yield.
Interventions
- PROCEDURE Apheresis
- DRUG Plerixafor
- DRUG Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-02-22 |
| Est. Completion | 2018-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547806
The ClinicalTrials.gov registry entry for NCT01547806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Apheresis is the first listed.
NCT01547806 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01547806 about?
NCT01547806 is a clinical study titled "Collection of Transplant Stem Cells for Plasma Cell Myeloma". Background: \- One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant. Objectives: \- To collect stem cells for transplant as part of treatment for plasma cell myeloma....
What is the current status of trial NCT01547806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2012-02-22. Estimated completion is 2018-01-11.
What interventions are being tested in trial NCT01547806?
The interventions under investigation include: Apheresis (PROCEDURE), Plerixafor (DRUG), Filgrastim (DRUG).
Who is sponsoring clinical trial NCT01547806?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.